Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex

Springer Science and Business Media LLC - Tập 15 - Trang 1-7 - 2015
Xin Su1, Angela Nickles2, Dwight E. Nelson1
1Medtronic plc, Neuromodulation Research, Minneapolis, USA
2Physiological Research Laboratories, Minneapolis, USA

Tóm tắt

While botulinum toxin A (BoNT-A) has become a more commonly used second-line treatment for patients with detrusor overactivity, it remains unknown whether the impacts of this therapy may persist to influence other therapies such as sacral neuromodulation. In this preclinical study we have evaluated urodynamic functions to intradetrusor injection of BoNT-A and the bladder inhibitory effects of spinal nerve stimulation (SNS) following BoNT-A treatment. Female rats were anesthetized with 3 % isoflurane. BoNT-A (2 units, 0.2 ml) or saline were injected into the detrusor. Rats then were housed for 2 days to 1 month before neuromodulation study. Monopolar electrodes were placed under each of the L6 spinal nerve bilaterally under urethane anesthesia. A bladder cannula was inserted via the urethra for saline infusion and intravesical pressure recording. Intradetrusor injection of BoNT-A for 1–2 weeks or 1 month significantly increased bladder capacity compared with saline injection (p < 0.05, two-way ANOVA). Following BoNT-A, SNS attenuated the frequency of bladder contractions, either eliminating bladder contractions or reducing the contraction frequency during electrical stimulation. Inhibition of the contraction frequency by SNS following BoNT-A treated rats was not different from that measured following saline injection. BoNT-A increased the bladder capacity, but compensating for additional saline infusion to the enlarged urinary bladder in BoNT-A pretreated rats, the bladder contractions induced by bladder filling were attenuated by SNS. BoNT-A did not alter the ability of SNS to inhibit bladder contraction following intradetrusor injection of BoNT-A for 2 days, 1–2 weeks or 1 month. These results support further pre-clinical and clinical studies to evaluate potential interactions or combination therapy with neuromodulation and intradetrusor BoNT-A therapeutic approaches.

Tài liệu tham khảo

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755–65. Hussain Z, Harrison SVW. Neuromodulation for lower urinary tract dysfunction – an update. Sci World J. 2007;7:1036–45. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55:100–20. Smith CP. Botulinum toxin in the treatment of OAB, BPH, and IC. Toxicon. 2009;54:639–46. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61:165–71. Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology. 2005;65:622–6. Krhut J, Zvara P. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int Urol Nephrol. 2011;43:337–43. Cayan S, Coşkun B, Bozlu M, Acar D, Akbay E, Ulusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res. 2003;30:399–404. Behr-Roussel D, Oger S, Pignol B, Pham E, Le Maux A, Chabrier PE, et al. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity. Eur Urol. 2012;61:1054–61. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urol. 2005;66:208–12. Smits MA, Oerlemans D, Marcelissen TA, Van Kerrebroeck PE, De Wachter SG. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. J Urol. 2013;190:2148–52. Su X, Nickles A, Nelson DE. Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat. Am J Physiol Renal Physiol. 2012;303:F1196–206. Su X, Nickles A, Nelson DE. Quantification of effectiveness of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model. BMC Urol. 2013;13:34. Su X, Nickles A, Nelson DE. Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat. Neurourol Urodyn. 2015;34:92–7. Su X, Nickles A, Nelson DE. Neuromodulation in a rat model of the bladder micturition reflex. Am J Physiol Renal Physiol. 2012;302:F477–86. Su X, Nickles A, Nelson DE. The role of the endogenous opioid system in modulation of urinary bladder activity by spinal nerve stimulation. Am J Physiol Renal Physiol. 2013;305:F53–60. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003;169:1896–900. Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox(®) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012;286:923–9. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int. 2008;52:1068–75. Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther. 2010;334:1080–6. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–70. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006;175:1138–42. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7. Sager C, Burek C, Durán V, Corbetta JP, Weller S, Juan B, et al. Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type A. ISRN Urol. 2012;2012:763159. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol. 2006;50:684–709. Elkelini MS, Bagli DJ, Fehlings M, Hassouna M. Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor. BJU Int. 2012;109:402–7. Munoz A, Somogyi GT, Boone TB, Smith CP. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. Neurourol Urodyn. 2011;30:1376–81. Noblett KL, Cadish LA. Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction. Am J Obstet Gynecol. 2014;210:99–106. Su X, Nickles A, Nelson DE. Neuromodulation attenuates bladder hyperactivity in a rat cystitis model. BMC Urol. 2013;13:70.